MedPath

Using Serious Game Technology to Improve Sensitivity to Eye Gaze in Autism

Phase 2
Completed
Conditions
Autism
Registration Number
NCT02968225
Lead Sponsor
Penn State University
Brief Summary

The investigators hypothesize that this serious game (designed to provide a learning environment that maximizes opportunities for adolescents with autism to discover the functional utility of eye gaze) will improve sensitivity to eye gaze cues, specifically to identify gazed-at objects, and will also lead to increased social attention to faces in adolescents with autism. The investigators will test this hypothesis in a small-scale exploratory randomized control trial that will include both behavioral and eye tracking outcome measures.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Social/Visual Attention Task2 Months

Eye tracking

Dynamic Eye Gaze Following Task2 Months

Eye tracking and accuracy

Static Eye Gaze Following Task2 months

Eye tracking and accuracy

Secondary Outcome Measures
NameTimeMethod
Social Skills Inventory System - Child version2 months

Adolescents completing measure of social skills and problem behaviors in themselves

Social Responsiveness Scale2 months

Parents completing measure of autism-like behavior in adolescents

Treatment as Usual2 months

Parents reporting on social and behavioral treatments adolescents receiving in and out of school

Social Skills Inventory System - Adult version2 months

Parents completing measure of social skills and problem behaviors in adolescents

Trial Locations

Locations (1)

Pennsylvania State University

🇺🇸

University Park, Pennsylvania, United States

Pennsylvania State University
🇺🇸University Park, Pennsylvania, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.